サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1543899

抗炎症治療薬の世界市場

Anti-Inflammatory Therapeutics

出版日
ページ情報
英文 194 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
抗炎症治療薬の世界市場
出版日: 2024年08月29日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 194 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

抗炎症治療薬の世界市場は2030年までに1,522億米ドルに達する見込み

2023年に1,131億米ドルと推定された抗炎症治療薬の世界市場は、分析期間2023-2030年にCAGR 4.3%で成長し、2030年には1,522億米ドルに達すると予測されます。本レポートで分析したセグメントの一つである抗炎症生物製剤は、CAGR 4.4%を記録し、分析期間終了時には677億米ドルに達すると予測されます。非ステロイド性抗炎症薬（NSAIDs）分野の成長率は、分析期間中CAGR 4.6%と推定されます。

米国市場は299億米ドル、中国はCAGR6.6%で成長予測

米国の抗炎症治療薬市場は2023年に299億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに326億米ドルの市場規模に達すると予測され、分析期間2023-2030年のCAGRは6.6%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ2.7%と3.4%と予測されています。欧州では、ドイツがCAGR 3.2%で成長すると予測されています。

世界の抗炎症治療薬市場- 主要動向と促進要因のまとめ

現代のヘルスケアにおける抗炎症治療薬の重要性

抗炎症治療薬は、多くの慢性・急性疾患の重要な要因である炎症を管理・緩和する上で極めて重要な役割を果たすため、現代ヘルスケアに不可欠です。自然な防御機構である炎症は、慢性化すると問題となり、関節リウマチ、炎症性腸疾患、心血管障害などの疾患の原因となります。非ステロイド性抗炎症薬（NSAIDs）、コルチコステロイド、生物学的製剤を含む抗炎症薬は、炎症と痛みを抑え、患者のQOLを著しく向上させるために不可欠です。これらの薬剤は様々な医療分野で広く使用されており、急性期治療と長期的な疾患管理の両方における重要性が強調されています。

抗炎症薬開発を促進する技術革新とは？

技術革新は抗炎症薬の開発に革命をもたらし、より正確で効果的な治療につながっています。バイオテクノロジーと分子生物学におけるブレークスルーは、炎症経路を特異的に標的とする生物学的療法への道を開いた。モノクローナル抗体やサイトカイン阻害剤などの生物学的製剤は、免疫系を選択的に調節することで標的治療を提供し、従来の薬剤に比べ大きな利点をもたらします。ゲノミクスとプロテオミクスの進歩により、新たな治療標的が特定されつつあり、次世代の抗炎症剤の創製が容易になりつつあります。さらに、徐放性製剤や標的送達システムなどのドラッグデリバリー技術の向上により、これらの治療薬の有効性と安全性が強化され、副作用が最小限に抑えられ、患者のアドヒアランスが向上しています。

なぜ抗炎症治療薬の需要は健康状態全体にわたって増加しているのでしょうか？

抗炎症治療薬の需要が急増しているのは、慢性炎症性疾患の罹患率が上昇し、炎症が多くの健康状態に関与していることが認識されつつあるためです。関節炎、喘息、炎症性腸疾患のような慢性疾患は世界的に数百万人に影響を与えており、効果的な抗炎症治療に対する大きなニーズを引き起こしています。さらに、高齢化社会は慢性炎症性疾患に罹患しやすく、これらの治療薬に対する需要を高めています。手術や怪我、感染症に起因する急性炎症反応もまた、効果的な管理が必要であり、抗炎症薬の適用範囲の広さを際立たせています。さらに、炎症とがんや神経変性疾患などの疾患との関連性に関する研究が拡大するにつれ、新規治療薬の開発が促進され、その応用範囲と市場ポテンシャルが拡大しています。

抗炎症治療薬市場の成長を促進する要因とは？

抗炎症治療薬市場の成長は、技術の進歩、炎症性疾患の有病率の上昇、治療パラダイムの進化など、いくつかの重要な要因によってもたらされます。バイオテクノロジーと個別化医療における技術革新は、より的を絞った効果的な生物学的製剤の創製につながっており、その精度の高さと副作用の軽減から、ますます好まれるようになっています。関節炎や炎症性腸疾患などの慢性炎症性疾患の罹患率の増加は、特に高齢化社会における重要な促進要因です。さらに、ヘルスケア支出の増加や医療サービスへのアクセスの向上により、炎症性疾患の治療を受けられる患者が増加しています。様々な疾患における炎症の役割に対する認識の高まりが研究開発に拍車をかけ、アンメット・メディカル・ニーズに対応する革新的な治療薬が生み出されています。さらに、製薬業界における戦略的提携やパートナーシップは、新たな抗炎症薬の開発と商業化を加速させ、市場の活気と拡大に貢献しています。

調査対象企業の例（注目の42社）

  • AbbVie, Inc.
  • Amgen, Inc.
  • AstraZeneca PLC
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer, Inc.

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP10311

Global Anti-Inflammatory Therapeutics Market to Reach US$152.2 Billion by 2030

The global market for Anti-Inflammatory Therapeutics estimated at US$113.1 Billion in the year 2023, is expected to reach US$152.2 Billion by 2030, growing at a CAGR of 4.3% over the analysis period 2023-2030. Anti-Inflammatory Biologics, one of the segments analyzed in the report, is expected to record a 4.4% CAGR and reach US$67.7 Billion by the end of the analysis period. Growth in the Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) segment is estimated at 4.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$29.9 Billion While China is Forecast to Grow at 6.6% CAGR

The Anti-Inflammatory Therapeutics market in the U.S. is estimated at US$29.9 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$32.6 Billion by the year 2030 trailing a CAGR of 6.6% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.7% and 3.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.2% CAGR.

Global Anti-Inflammatory Therapeutics Market - Key Trends and Drivers Summarized

How Essential Are Anti-Inflammatory Therapeutics in Modern Healthcare?

Anti-inflammatory therapeutics are integral to modern healthcare due to their pivotal role in managing and alleviating inflammation, a key factor in numerous chronic and acute conditions. Inflammation, a natural defense mechanism, becomes problematic when chronic, contributing to diseases such as rheumatoid arthritis, inflammatory bowel disease, and cardiovascular disorders. Anti-inflammatory drugs, including non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and biologics, are essential for reducing inflammation and pain, thereby significantly enhancing patient quality of life. These medications are widely used across various medical fields, highlighting their critical importance in both acute care and long-term disease management.

What Technological Innovations Are Advancing Anti-Inflammatory Drug Development?

Technological innovations are revolutionizing the development of anti-inflammatory drugs, leading to more precise and effective treatments. Breakthroughs in biotechnology and molecular biology have paved the way for biologic therapies that specifically target inflammatory pathways. Biologics, such as monoclonal antibodies and cytokine inhibitors, offer targeted treatment by selectively modulating the immune system, providing a significant advantage over traditional drugs. Advances in genomics and proteomics are identifying new therapeutic targets, facilitating the creation of next-generation anti-inflammatory agents. Additionally, improvements in drug delivery technologies, including sustained-release formulations and targeted delivery systems, are enhancing the efficacy and safety of these therapies, minimizing side effects and boosting patient adherence.

Why Is Demand for Anti-Inflammatory Therapeutics Increasing Across Health Conditions?

The demand for anti-inflammatory therapeutics is surging due to the rising incidence of chronic inflammatory diseases and the growing recognition of inflammation's role in numerous health conditions. Chronic conditions like arthritis, asthma, and inflammatory bowel disease impact millions globally, driving a substantial need for effective anti-inflammatory treatments. Furthermore, the aging population is more prone to chronic inflammatory ailments, increasing the demand for these therapeutics. Acute inflammatory responses, resulting from surgeries, injuries, and infections, also necessitate effective management, underscoring the wide-ranging applicability of anti-inflammatory drugs. Additionally, expanding research into the connection between inflammation and diseases such as cancer and neurodegenerative disorders is fostering the development of novel therapies, broadening their application and market potential.

What Factors Are Propelling Growth in the Anti-Inflammatory Therapeutics Market?

The growth in the anti-inflammatory therapeutics market is driven by several key factors, including technological advancements, the rising prevalence of inflammatory diseases, and evolving treatment paradigms. Innovations in biotechnology and personalized medicine are leading to the creation of more targeted and effective biologic therapies, which are increasingly preferred for their precision and reduced side effects. The growing incidence of chronic inflammatory conditions, such as arthritis and inflammatory bowel disease, is a significant driver, particularly among the aging population. Additionally, increasing healthcare expenditure and improved access to medical services are enabling more patients to receive treatment for inflammatory conditions. Enhanced awareness of inflammation's role in various diseases is fueling research and development, resulting in innovative therapies that address unmet medical needs. Furthermore, strategic collaborations and partnerships within the pharmaceutical industry are accelerating the development and commercialization of new anti-inflammatory drugs, contributing to a vibrant and expanding market landscape.

Select Competitors (Total 42 Featured) -

  • AbbVie, Inc.
  • Amgen, Inc.
  • AstraZeneca PLC
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Anti-Inflammatory Therapeutics - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
    • Global Economic Update
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Chronic Inflammatory Diseases Throws the Spotlight on Anti-Inflammatory Therapeutics
    • Advances in Biotechnology and Personalized Medicine Propel Growth in Therapeutic Options
    • Development of Biologic Therapies Expands Addressable Market Opportunity
    • Increasing Prevalence of Autoimmune Disorders Strengthens Business Case for Anti-Inflammatory Drugs
    • Growing Focus on Targeted Therapies and Precision Medicine Spurs Market Growth
    • Rising Awareness of Inflammation's Role in Chronic Diseases Propels Demand for Innovative Treatments
    • Integration of Anti-Inflammatory Drugs in Comprehensive Care Plans Expands Market Reach
    • Trends in Personalized Healthcare Drive Adoption of Advanced Anti-Inflammatory Solutions
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Anti-Inflammatory Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Anti-Inflammatory Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 3: World 16-Year Perspective for Anti-Inflammatory Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Anti-Inflammatory Biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Anti-Inflammatory Biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 6: World 16-Year Perspective for Anti-Inflammatory Biologics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 9: World 16-Year Perspective for Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 12: World 16-Year Perspective for Corticosteroids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Arthritis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 14: World Historic Review for Arthritis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 15: World 16-Year Perspective for Arthritis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Respiratory Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 17: World Historic Review for Respiratory Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 18: World 16-Year Perspective for Respiratory Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 19: World Recent Past, Current & Future Analysis for Multiple Sclerosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 20: World Historic Review for Multiple Sclerosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 21: World 16-Year Perspective for Multiple Sclerosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Psoriasis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 23: World Historic Review for Psoriasis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 24: World 16-Year Perspective for Psoriasis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 25: World Recent Past, Current & Future Analysis for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 26: World Historic Review for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 27: World 16-Year Perspective for Other Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 28: World Anti-Inflammatory Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Inflammatory Bowel Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Inflammatory Bowel Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: World 16-Year Perspective for Inflammatory Bowel Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Anti-Inflammatory Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 32: USA Recent Past, Current & Future Analysis for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: USA 16-Year Perspective for Anti-Inflammatory Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids for the Years 2014, 2024 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: USA 16-Year Perspective for Anti-Inflammatory Therapeutics by Indication - Percentage Breakdown of Value Sales for Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: Canada 16-Year Perspective for Anti-Inflammatory Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids for the Years 2014, 2024 & 2030
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: Canada 16-Year Perspective for Anti-Inflammatory Therapeutics by Indication - Percentage Breakdown of Value Sales for Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications for the Years 2014, 2024 & 2030
  • JAPAN
    • Anti-Inflammatory Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: Japan 16-Year Perspective for Anti-Inflammatory Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids for the Years 2014, 2024 & 2030
    • TABLE 47: Japan Recent Past, Current & Future Analysis for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Japan Historic Review for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: Japan 16-Year Perspective for Anti-Inflammatory Therapeutics by Indication - Percentage Breakdown of Value Sales for Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications for the Years 2014, 2024 & 2030
  • CHINA
    • Anti-Inflammatory Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 50: China Recent Past, Current & Future Analysis for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: China Historic Review for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: China 16-Year Perspective for Anti-Inflammatory Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids for the Years 2014, 2024 & 2030
    • TABLE 53: China Recent Past, Current & Future Analysis for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: China Historic Review for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: China 16-Year Perspective for Anti-Inflammatory Therapeutics by Indication - Percentage Breakdown of Value Sales for Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications for the Years 2014, 2024 & 2030
  • EUROPE
    • Anti-Inflammatory Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Anti-Inflammatory Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Anti-Inflammatory Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: Europe 16-Year Perspective for Anti-Inflammatory Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: Europe 16-Year Perspective for Anti-Inflammatory Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids for the Years 2014, 2024 & 2030
    • TABLE 62: Europe Recent Past, Current & Future Analysis for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Europe Historic Review for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: Europe 16-Year Perspective for Anti-Inflammatory Therapeutics by Indication - Percentage Breakdown of Value Sales for Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications for the Years 2014, 2024 & 2030
  • FRANCE
    • Anti-Inflammatory Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 65: France Recent Past, Current & Future Analysis for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: France Historic Review for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: France 16-Year Perspective for Anti-Inflammatory Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids for the Years 2014, 2024 & 2030
    • TABLE 68: France Recent Past, Current & Future Analysis for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: France Historic Review for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: France 16-Year Perspective for Anti-Inflammatory Therapeutics by Indication - Percentage Breakdown of Value Sales for Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications for the Years 2014, 2024 & 2030
  • GERMANY
    • Anti-Inflammatory Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 71: Germany Recent Past, Current & Future Analysis for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Germany Historic Review for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: Germany 16-Year Perspective for Anti-Inflammatory Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids for the Years 2014, 2024 & 2030
    • TABLE 74: Germany Recent Past, Current & Future Analysis for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Germany Historic Review for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: Germany 16-Year Perspective for Anti-Inflammatory Therapeutics by Indication - Percentage Breakdown of Value Sales for Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 77: Italy Recent Past, Current & Future Analysis for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Italy Historic Review for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: Italy 16-Year Perspective for Anti-Inflammatory Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids for the Years 2014, 2024 & 2030
    • TABLE 80: Italy Recent Past, Current & Future Analysis for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Italy Historic Review for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: Italy 16-Year Perspective for Anti-Inflammatory Therapeutics by Indication - Percentage Breakdown of Value Sales for Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Anti-Inflammatory Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 83: UK Recent Past, Current & Future Analysis for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: UK Historic Review for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: UK 16-Year Perspective for Anti-Inflammatory Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids for the Years 2014, 2024 & 2030
    • TABLE 86: UK Recent Past, Current & Future Analysis for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: UK Historic Review for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: UK 16-Year Perspective for Anti-Inflammatory Therapeutics by Indication - Percentage Breakdown of Value Sales for Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 89: Spain Recent Past, Current & Future Analysis for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Spain Historic Review for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: Spain 16-Year Perspective for Anti-Inflammatory Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids for the Years 2014, 2024 & 2030
    • TABLE 92: Spain Recent Past, Current & Future Analysis for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Spain Historic Review for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Spain 16-Year Perspective for Anti-Inflammatory Therapeutics by Indication - Percentage Breakdown of Value Sales for Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 95: Russia Recent Past, Current & Future Analysis for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Russia Historic Review for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Russia 16-Year Perspective for Anti-Inflammatory Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids for the Years 2014, 2024 & 2030
    • TABLE 98: Russia Recent Past, Current & Future Analysis for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Russia Historic Review for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Russia 16-Year Perspective for Anti-Inflammatory Therapeutics by Indication - Percentage Breakdown of Value Sales for Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Rest of Europe Historic Review for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Rest of Europe 16-Year Perspective for Anti-Inflammatory Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids for the Years 2014, 2024 & 2030
    • TABLE 104: Rest of Europe Recent Past, Current & Future Analysis for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Rest of Europe Historic Review for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Rest of Europe 16-Year Perspective for Anti-Inflammatory Therapeutics by Indication - Percentage Breakdown of Value Sales for Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Anti-Inflammatory Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Anti-Inflammatory Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Anti-Inflammatory Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: Asia-Pacific 16-Year Perspective for Anti-Inflammatory Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific Historic Review for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: Asia-Pacific 16-Year Perspective for Anti-Inflammatory Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids for the Years 2014, 2024 & 2030
    • TABLE 113: Asia-Pacific Recent Past, Current & Future Analysis for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 114: Asia-Pacific Historic Review for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 115: Asia-Pacific 16-Year Perspective for Anti-Inflammatory Therapeutics by Indication - Percentage Breakdown of Value Sales for Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Anti-Inflammatory Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 116: Australia Recent Past, Current & Future Analysis for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 117: Australia Historic Review for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 118: Australia 16-Year Perspective for Anti-Inflammatory Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids for the Years 2014, 2024 & 2030
    • TABLE 119: Australia Recent Past, Current & Future Analysis for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 120: Australia Historic Review for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 121: Australia 16-Year Perspective for Anti-Inflammatory Therapeutics by Indication - Percentage Breakdown of Value Sales for Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications for the Years 2014, 2024 & 2030
  • INDIA
    • Anti-Inflammatory Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 122: India Recent Past, Current & Future Analysis for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 123: India Historic Review for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 124: India 16-Year Perspective for Anti-Inflammatory Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids for the Years 2014, 2024 & 2030
    • TABLE 125: India Recent Past, Current & Future Analysis for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 126: India Historic Review for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 127: India 16-Year Perspective for Anti-Inflammatory Therapeutics by Indication - Percentage Breakdown of Value Sales for Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 128: South Korea Recent Past, Current & Future Analysis for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 129: South Korea Historic Review for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 130: South Korea 16-Year Perspective for Anti-Inflammatory Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids for the Years 2014, 2024 & 2030
    • TABLE 131: South Korea Recent Past, Current & Future Analysis for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 132: South Korea Historic Review for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 133: South Korea 16-Year Perspective for Anti-Inflammatory Therapeutics by Indication - Percentage Breakdown of Value Sales for Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Rest of Asia-Pacific Historic Review for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 136: Rest of Asia-Pacific 16-Year Perspective for Anti-Inflammatory Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids for the Years 2014, 2024 & 2030
    • TABLE 137: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Rest of Asia-Pacific Historic Review for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 139: Rest of Asia-Pacific 16-Year Perspective for Anti-Inflammatory Therapeutics by Indication - Percentage Breakdown of Value Sales for Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Anti-Inflammatory Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Anti-Inflammatory Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Anti-Inflammatory Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 142: Latin America 16-Year Perspective for Anti-Inflammatory Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 143: Latin America Recent Past, Current & Future Analysis for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Latin America Historic Review for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 145: Latin America 16-Year Perspective for Anti-Inflammatory Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids for the Years 2014, 2024 & 2030
    • TABLE 146: Latin America Recent Past, Current & Future Analysis for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Latin America Historic Review for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 148: Latin America 16-Year Perspective for Anti-Inflammatory Therapeutics by Indication - Percentage Breakdown of Value Sales for Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 149: Argentina Recent Past, Current & Future Analysis for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Argentina Historic Review for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 151: Argentina 16-Year Perspective for Anti-Inflammatory Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids for the Years 2014, 2024 & 2030
    • TABLE 152: Argentina Recent Past, Current & Future Analysis for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Argentina Historic Review for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 154: Argentina 16-Year Perspective for Anti-Inflammatory Therapeutics by Indication - Percentage Breakdown of Value Sales for Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 155: Brazil Recent Past, Current & Future Analysis for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Brazil Historic Review for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 157: Brazil 16-Year Perspective for Anti-Inflammatory Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids for the Years 2014, 2024 & 2030
    • TABLE 158: Brazil Recent Past, Current & Future Analysis for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Brazil Historic Review for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 160: Brazil 16-Year Perspective for Anti-Inflammatory Therapeutics by Indication - Percentage Breakdown of Value Sales for Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 161: Mexico Recent Past, Current & Future Analysis for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 162: Mexico Historic Review for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 163: Mexico 16-Year Perspective for Anti-Inflammatory Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids for the Years 2014, 2024 & 2030
    • TABLE 164: Mexico Recent Past, Current & Future Analysis for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 165: Mexico Historic Review for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 166: Mexico 16-Year Perspective for Anti-Inflammatory Therapeutics by Indication - Percentage Breakdown of Value Sales for Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 168: Rest of Latin America Historic Review for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 169: Rest of Latin America 16-Year Perspective for Anti-Inflammatory Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids for the Years 2014, 2024 & 2030
    • TABLE 170: Rest of Latin America Recent Past, Current & Future Analysis for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 171: Rest of Latin America Historic Review for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 172: Rest of Latin America 16-Year Perspective for Anti-Inflammatory Therapeutics by Indication - Percentage Breakdown of Value Sales for Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Anti-Inflammatory Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Anti-Inflammatory Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Anti-Inflammatory Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 175: Middle East 16-Year Perspective for Anti-Inflammatory Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 176: Middle East Recent Past, Current & Future Analysis for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 177: Middle East Historic Review for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 178: Middle East 16-Year Perspective for Anti-Inflammatory Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids for the Years 2014, 2024 & 2030
    • TABLE 179: Middle East Recent Past, Current & Future Analysis for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 180: Middle East Historic Review for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 181: Middle East 16-Year Perspective for Anti-Inflammatory Therapeutics by Indication - Percentage Breakdown of Value Sales for Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 182: Iran Recent Past, Current & Future Analysis for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 183: Iran Historic Review for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 184: Iran 16-Year Perspective for Anti-Inflammatory Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids for the Years 2014, 2024 & 2030
    • TABLE 185: Iran Recent Past, Current & Future Analysis for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 186: Iran Historic Review for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 187: Iran 16-Year Perspective for Anti-Inflammatory Therapeutics by Indication - Percentage Breakdown of Value Sales for Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 188: Israel Recent Past, Current & Future Analysis for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 189: Israel Historic Review for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 190: Israel 16-Year Perspective for Anti-Inflammatory Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids for the Years 2014, 2024 & 2030
    • TABLE 191: Israel Recent Past, Current & Future Analysis for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 192: Israel Historic Review for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 193: Israel 16-Year Perspective for Anti-Inflammatory Therapeutics by Indication - Percentage Breakdown of Value Sales for Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 195: Saudi Arabia Historic Review for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 196: Saudi Arabia 16-Year Perspective for Anti-Inflammatory Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids for the Years 2014, 2024 & 2030
    • TABLE 197: Saudi Arabia Recent Past, Current & Future Analysis for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 198: Saudi Arabia Historic Review for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 199: Saudi Arabia 16-Year Perspective for Anti-Inflammatory Therapeutics by Indication - Percentage Breakdown of Value Sales for Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 200: UAE Recent Past, Current & Future Analysis for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 201: UAE Historic Review for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 202: UAE 16-Year Perspective for Anti-Inflammatory Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids for the Years 2014, 2024 & 2030
    • TABLE 203: UAE Recent Past, Current & Future Analysis for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 204: UAE Historic Review for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 205: UAE 16-Year Perspective for Anti-Inflammatory Therapeutics by Indication - Percentage Breakdown of Value Sales for Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 207: Rest of Middle East Historic Review for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 208: Rest of Middle East 16-Year Perspective for Anti-Inflammatory Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids for the Years 2014, 2024 & 2030
    • TABLE 209: Rest of Middle East Recent Past, Current & Future Analysis for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 210: Rest of Middle East Historic Review for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 211: Rest of Middle East 16-Year Perspective for Anti-Inflammatory Therapeutics by Indication - Percentage Breakdown of Value Sales for Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications for the Years 2014, 2024 & 2030
  • AFRICA
    • Anti-Inflammatory Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 212: Africa Recent Past, Current & Future Analysis for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 213: Africa Historic Review for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 214: Africa 16-Year Perspective for Anti-Inflammatory Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids for the Years 2014, 2024 & 2030
    • TABLE 215: Africa Recent Past, Current & Future Analysis for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 216: Africa Historic Review for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 217: Africa 16-Year Perspective for Anti-Inflammatory Therapeutics by Indication - Percentage Breakdown of Value Sales for Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and Other Indications for the Years 2014, 2024 & 2030

IV. COMPETITION